

GOG-P – Improving Care of Women's Cancer – TiP of the Iceberg

Independent Satellite Symposia during The SGO Virtual Annual Meeting on Women's Cancer®

Wednesday, March 24, 2021

GOG CONFIDENTIALITY NOTICE

- **This presentation is the property of The GOG Foundation, Inc. (“GOG”) and/or our Sponsors and is strictly confidential. It contains information intended only for the person to whom it is transmitted and is not to be shared with any third party without the prior written consent of the GOG General Counsel.**
- **With receipt of this information, recipient acknowledges and agrees that: (i) this document is not to be distributed; (ii) the recipient will not copy, duplicate, photograph, reproduce, divulge, or distribute this confidential information, in whole or in part, without the express written consent of the GOG General Counsel; and (iii) all of the information herein will be treated as confidential material with no less care than that afforded to its own confidential material.**

GOG FACULTY DISCLOSURE INFORMATION

Virtual Symposium, “Improving Care of Women’s Cancer- TIP of the Iceberg”

March 24, 2021

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc. as the accredited provider of this activity must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Members of the Program Committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a “commercial interest” as any entity producing, marketing, re- selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 12 months that may create a conflict of interest.

All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

NAME	NOTHING TO DISCLOSE	DISCLOSURE
Speakers/Moderators		
Robert Coleman, MD		Honorarium: Abbvie, Agenesis, Alkermes, AstraZeneca, Clovis, Epsilogen, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Thomas Herzog, MD		Advisory Board: Aravive, AstraZeneca, Caris, Clovis, Eisai, Genentech, GSK, Johnson & Johnson, Merck
Bradley Monk, MD		Honorarium: Agenesis, Akeso Bio, Aravive, AstraZeneca, Clovis, Easai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, McKesson/US Oncology, Mersana, Novocure, Myriad, Pfizer, Puma, Roche/Genentech, Sorrento, Tesaro/GSK,
Kathleen Moore, MD		Consulting Honorarium: Aravive, Astra Zeneca, Abbvie, Eisai, Immunogen, GSK/Tesaro, Genentech/roche, Mersana, Merck, Tarveda, VBL Therapeutics, Vavotar, Myriad, Perthera Study PI- Research support: PTC Therapeutics, Lilly, Genentech, Merck
David O'Malley, MD		Honorarium: Roche Diagnostics, Watermark, Immunogen, AstraZeneca, Sorrento, Rubius, Elevar, Novartis, Eisai, GSK,Novocure, Genentech, GOG Foundation, Mersana, Seattle Genetics, Ambry, Regeneron, Myriad, GSK/Tesaro, Agenesis
Leslie Randall, MD		Consulting fee: Agenesis, Clovis, Myriad, Mersana, GSK/Tesaro Research rant /Contractor: Merck, Pfizer
Brian Slomovitz, MD		Consulting and Honorarium: Abbvie: Astra Zeneca: Clovis: GSM: Genentech:Merck: Myriad
Planning Committee Members		
Robert Coleman, MD		Honorarium: Abbvie, Agenesis, Alkermes, AstraZeneca, Clovis, Epsilogen, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Bradley Monk, MD		Honorarium: Agenesis, Akeso Bio, Aravive, AstraZeneca, Clovis, Easai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, McKesson/US Oncology, Mersana, Novocure, Myriad, Pfizer, Puma, Roche/Genentech, Sorrento, Tesaro/GSK,

GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™


The GOG Foundation, Inc. designates this live activity for a maximum of **1.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

AGENDA



6:45 pm – 6:49 pm

Introduction

Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA

6:49 pm – 6:55 pm

History and Structure of GOG-P

Robert L. Coleman, MD, US Oncology Research, Houston, Texas, USA

6:55 pm – 7:13 pm

Current GOG-P clinical trials: Uterine

Brian Slomovitz, MD, Florida International University, Broward Health, Fort Lauderdale, Florida, USA

7:13 pm – 7:23 pm

Current GOG-P clinical trials: Cervix

Leslie Randall, MD, VCU Health System, MCV Physicians, Richmond, Virginia, USA

7:23 pm – 7:45pm

Current GOG-P clinical trials: Ovarian

David O'Malley, MD, The Ohio State University Medical Center, Columbus, Ohio, USA

7:45 pm – 7:51 pm

Investigator Council Overview

Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA

Kathleen N. Moore, MD, Oklahoma University HSC, Oklahoma City, Oklahoma, USA

7:51 pm – 8:00 pm

Future Directions and Discussion

Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA

CONFIDENTIAL